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Abstract: Background: Irritable bowel syndrome (IBS) is a functional disorder without any 
pathological alteration, in which the alterations of the Candida/Saccharomyces ratio of the gut 
microbiota, the balance of pro and anti-inflammatory cytokines and the brain-gut-microbiome axis 
are important for the development and progression of IBS. The aim of the study was to identify 
natural products, including essential oils or hydrolates, which were contextually harmless for the 
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gut beneficial strains (e.g. Saccharomyces spp.) but inhibitory for the pathogenic ones (Candida spp.). 
Methods: The effectiveness of 6 essential oils and 2 hydrolates was evaluated using microbiological 
tests, carried out on 50 clinical isolates (Candida, Saccharomyces and Galattomyces species) and 9 
probiotic strains (Saccharomyces cerevisiae, Lactobacillus species, Akkermansia muciniphila and 
Faecalibacterium prausnitzii) and immunological and antioxidant assays. Results: The study led to a 
mixture based on a 1/100 ratio of Citrus aurantium var. amara essential oil / Vitis vinifera cv Italia 
hydrolate able to contextually reduce, in a concentration-dependent manner, the ability of Candida 
species to form hyphal filaments and have an interesting immunomodulatory and anti-oxidant 
action. This mixture can potentially be useful in the IBS treatment promoting the restoration of the 
intestinal microbial and immunological balance. 
Keywords: Candida species; Saccharomyces cerevisiae; Citrus aurantium var. amara essential oil; Vitis 
vinifera cv Italia hydrolate; Akkermansia muciniphila  
 
1. Introduction 
Irritable bowel syndrome (IBS) is a gastrointestinal disorder that affects around 11% of the 
population globally [1]. Despite being a chronic condition, contrary to the intestinal bowel disease 
(IBD) that is a chronic inflammation of the intestine, IBS is a functional disorder without any 
pathological alteration identified to date. However, IBS usually involves the brain-gut-microbiome 
axis but it can develop after an enteric infection, with the stress exacerbating the disorder-associated 
symptoms [2]. Symptoms reported in either IBS or IBD patients are almost the same but differ with 
respect to their extent. Generally, patients with IBD have more severe gastrointestinal symptoms 
compared with IBS. [3]. There is a growing evidence that the gut microbiota alteration (e.g. decrease 
in the relative abundance of a beneficial microorganism like Akkermansia muciniphila) and the 
psychology of the patient are both important for the development and progression of IBS [2]. Since 
1985, authors have correlated the presence of Candida species in the intestinal tract with IBS [4] but 
only twenty years later other authors showed that yeasts are able to cause IBS symptoms in patients 
sensitized by Candida products, antigens and cross-antigens [5]. Other studies showed that the 
integration of Saccharomyces cerevisiae in the diet of patients with IBS was able to significantly reduce 
abdominal pain/discomfort and bloating and to improve the minimal clinically relevant threshold up 
to 10% [6–8]. In 2018, another study reported on the association between the relative abundance of A. 
muciniphila and the pain modulation in IBS patients [9]. Finally, studies showed that the concomitant 
decrease in the abundance of Saccharomyces species (i.e., S. cerevisiae and S. cerevisiae var. boulardii) 
and the increase of Candida species in the intestinal or vaginal microbial communities correlated with 
a decreased expression of the anti-inflammatory cytokine IL-10 and an increased expression of the 
pro-inflammatory cytokines IL-6, IL-8 and TNF- [10–13]. 
Integrated treatments for IBS include the combined administration of conventional and 
complementary medications. The latter encompass Chinese medicine, homeopathy and 
phytotherapy [14,15]. Several studies have recently evaluated the efficacy of natural products, such 
as essential oils (EOs), in the treatment of IBS symptoms [16–22]. Some of the EOs studied derive 
from aromatic plants of the Mediterranean area, such as Foeniculum vulgare, Pimpinella anisum, Mentha 
× piperita and Citrus aurantium. The most active components of EOs are terpenes, whereas the 
hydrophilic hydrolates (Hys) are by-products of EO distillation (also known as hydrolates or 
aromatic waters) that contain up to 1% terpenic components of the EOs [23]. 
The aim of the present study was to evaluate the effectiveness of six EOs and two Hys, alone or 
in combination, on both yeast (Candida, Saccharomyces and Galattomyces) isolates from IBS patients 
and probiotic strains (Saccharomyces and Lactobacillus). 
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2. Materials and Methods  
2.1. EO and Hy Natural Substances 
The six EOs studied were as follows—Citrus lemon var. femminello (femminello lemon), supplied 
by Exentiae Srl (Catania, Italy); C. aurantium var. amara (bitter orange), Citrus lemon (lemon) and Citrus 
reticulata (mandarin), supplied by Misitano and Stracuzzi Company (Messina, Italy); Monarda didyma 
(bee balm), supplied by the DISTAL of the Università di Bologna (Bologna, Italy) [24]; and 
Cinnamomum zeylanicum (cinnamon) supplied by APA-Ct (Forlì, Italy). All the Citrus species EOs 
were obtained from their respective fruit epicarps by pressing, whereas the M. didyma EO was 
obtained from the plant aerial parts and the C. zeylanicum EO was obtained from the cortex, both 
through steam distillation. The two Hys studied were from M. didyma and Vitis vinifera cv Italia, 
supplied by DISTAL of the Università di Bologna (Bologna, Italy). In particular, the M. didyma Hy 
was obtained from the same distillation process as for the M. didyma EO [25], whereas V. vinifera, for 
the first time in this study, was obtained according to the following protocol. Briefly, vegetal material 
(ripe berries and grape-stalks) of the V. vinifera cv Italia was collected from the plants grown in the 
Sicily region, monitored with a visual inspection to eliminate the parts apparently infested by bacteria 
and/or fungi and cut in small pieces that were subjected to distillation in a Clevenger-type apparatus. 
After one hour of distillation, only a sample of Hy (no EO was visualized) was collected. 
2.2. Fungal and Bacterial Organisms 
Fifty clinical isolates of fungal species (29 Candida albicans, 3 Candida glabrata, 1 Candida krusei, 4 
Candida parapsilosis, 1 Candida zeylanoides, 8 Galactomyces species and 4 S. cerevisiae) were used, which 
had been recovered from fecal samples of IBS patients at the Dipartimento di Gastroenterologia e 
Epatologia, Ospedale G. da Saliceto of Piacenza, Italy. Patients were selected according to ROME III 
diagnostic criteria for IBS; all patients presented abdominal pain/discomfort for almost 3 days/weeks. 
The 62% of IBS patients had diarrhea (> 3 discharges / day) and the 38% suffered of constipation (<3 
discharges / weeks). The Institutional Review Board of the Dipartimento di Gastroenterologia e 
Epatologia, Ospedale “G. da Saliceto” of Piacenza, Italy, approved the protocol for the obtainment of 
the patients’ fecal samples. Isolation and identification of fungal cultivable single-cell pure colonies 
from stool sample of the IBS patients were performed as previously described [24]. Two fluconazole-
resistant Candida tropicalis isolates were also used, obtained from clinical stool samples of patients 
hospitalized at the Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome, Italy, only to 
evaluate the effectiveness of natural products on the fungal morphology. For comparison purposes, 
nine probiotic strains were included, five non-commercial strains (A. muciniphila DSMZ 22959, 
Faecalibacterium prausnitzii DSMZ17677, Lactobacillus acidophilus LA3SACCO, Lactobacillus plantarum 
ATCC 14917, Lactobacillus rhamnosus DSMZ 20021) and four commercial strains (S. boulardii CBS5926, 
L. acidophilus LA-14, Lactobacillus casei RO215, Lactobacillus helveticus ROO52). 
2.3. Broth Microdilution Susceptibility Testing 
Broth microdilution (BMD) susceptibility tests was performed on all the 59 microbial organisms 
according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
international guidelines. RPMI broth (Irvine Scientific, St. Ana, CA, USA) was used for fungal 
organisms, Man, Rogosa and Sharpe (MRS) broth (Sigma Aldrich, St. Louis, MO, USA) for 
Lactobacillus species organisms and Brucella broth (Thermo Scientific, West Sussex, UK) for A. 
muciniphila and F. prausnitzii organisms. All the bacterial probiotic strains were allowed to grow in 
an anaerobic condition. Briefly, for each organism a cell suspension equal to 5 × 105 cfu/mL was 
obtained and 50 μL of the suspension was dispensed in each well of a 96-well microtiter plate, which 
contained 50 μL of serial concentrations ranging from 4% v/v (40 mL/L) to 0.06% v/v (0.6 mL/L) for 
each EO and from 50% v/v (500 mL/L) to 1.67% v/v (16.7 mL/L) for each Hy. Tween 80 was utilized, 
at 0.05% v/v, as emulsifier for EO.  Suitable positive controls, only with culture medium, were made 
for each microbiological strain. After 24/48 hours of incubation at 37°C, minimum inhibitory 
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concentration (MIC) values were determined by spectrophotometric reading at 450 nm (EL808, 
Biotek, Winooski, VT, USA). To determine the minimum cytocidal concentration (MCC) or the 
minimum fungicidal concentration (MFC), 5 L of the content of each well were seeded on standard 
medium agar plates, which were incubated at 37°C for 24/48 hours. For each natural substance (EO 
or Hy)/organism combination tested, the MIC was defined as the lowest concentration that allowed 
a complete inhibition of the organism’s growth compared with the growth in the substance-free 
control and the MCC as the lowest concentration that allowed the death of 99.9% or more of the initial 
inoculum organism. All tests were performed in triplicate. For C. aurantium var. amara, C. zeylanicum 
or M. dydima EOs, the BMD susceptibility tests were also performed with co-cultures of two randomly 
selected organisms (i.e. C. albicans clinical isolate 3.1 and S. cerevisiae clinical isolate 14.3), starting 
from a 5 × 105 cfu/mL cell suspension obtained with a mixture (ratio 1:1) of the two isolates. Then, 10 
L of the content of each well showing the organism(s)’ visible growth was seeded on the Brilliance 
Candida agar chromogenic medium (Oxoid, Thermo Scientific, Basingstoke, UK) plates, which was 
incubated at 37°C for 48 hours. After incubation, the blue (C. albicans) and purple (S. cerevisiae) 
colonies were counted to obtain the cfu/mL values for each organism, respectively. Finally, to assess 
the effect of the C. aurantium var. amara EO and V. vinifera cv Italia combination, a checkerboard broth 
microdilution susceptibility testing was performed with the two cultured fungal organisms and sub-
MIC concentration of C. aurantium var. amara EO (from 0.50% v/v to 0.06%) and V. vinifera cv Italia 
Hy (from 0.25% v/v to 0.06% v/v). Then, the growth percentage at each combination’s concentration 
was determined as the ratio between the number of cfu/mL obtained for that concentration and the 
number of cfu/mL obtained for the substance-free control. Finally, the content of each well was 
visualized directly with an inverted microscope and, after scraping of the bottom (50 L), with an 
optical microscope to study the fungal morphology. 
2.4. Peripheral Blood Mononuclear Cell (PBMC) Collection and ELISA Testing 
Peripheral blood mononuclear cells (PBMCs) from human blood derived from refrigerated, 
banked healthy donor blood were collected with HISTOPAQUE-1077 (Sigma Aldrich, St. Louis, MO, 
USA) solution according to the manufacturer's protocol. After collection, 250 L of a suspension of 
1.2 × 106 cells/mL were cultured in sextuplicate in a 48-well cell culture plate at 37°C overnight. 
PBMCs were incubated in the presence of serial dilutions of the V. vinifera Hy (from 50% v/v to 6.25% 
v/v) alone or in combination with C. aurantium var. amara EO (from 0.50% v/v to 0.06% v/v) or with 
lipopolysaccharide (LPS, 1 g/mL). Untreated PBMC cells were used as control. After 24 h of 
incubation at 37°C, the content of 4 replicates was mixed and centrifuged (400 × g for 10 min at room 
temperature) to separate the cells from the culture medium, which was stored at -20°C until testing. 
The remaining two replicates were treated with 5 L of Alamar Blue reagent (Invitrogen, Carlsbad, 
CA, USA) in order to study the cellular vitality. To evaluate the expression of IL-6, IL-8, TNF- and 
IL-10 cytokines, ELISA tests (AVIVA Systems, San Diego, CA, USA) were performed using 100 L of 
the aforementioned culture medium, according to the manufacturer's instructions. In each well, the 
content of cytokines was evaluated with optical reading using a microplate reading set to 450 nm. A 
calibration curve with six serial dilutions of the standard was included in each experiment, which 
was repeated three times. 
2.5. DPPH (2,2-Diphenyl-1-Picryl-Hydrazyl-Hydrate) Assay 
The DPPH antioxidant assay was performed to evaluate the scavenging activity of the V. vinifera 
Hy. Serial dilutions of the Hy (100 L) were mixed with the 400-M DPPH solution (100 L) in a 96-
well microtiter plate. Methanol was used as a negative control. The mixtures were incubated for 30 
min at 37°C in the dark and the change in spectrophotometric absorbance at 517 nm was measured. 
Mean values were obtained from triplicate experiments. The percentage of radical scavenging activity 
per sample was calculated using the following equation:  
% inhibition = [(A DPPH – A Extract)/ADPPH] × 100, 
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where A DPPH is the absorbance of the DPPH solution only and A Extract is the absorbance of 
the tested sample. The IC50 value for the V. vinifera Hy was defined as the concentration of organic 
compound at which 50% of DPPH radicals was quenched and was expressed as mean ± standard 
deviation. 
2.6. GC-MS Analysis 
A V. vinifera cv Italia Hy sample (50 mL) was extracted with diethyl ether (100 mL). The collected 
organic layers dried over dry Na2SO4 and deprived of the solvent at reduced pressure furnished 
about 21.5 mg of an oily mixture (0.043%). The resulting Hy extract (1 mg) as well as a C. aurantium 
var. amara EO sample (1 mg) were separately diluted in 1mL methanol and used for Gas 
Chromatography-Mass Spectrometry (GC/MS) analysis. A GC-MS Perkin Elmer Clarus 500 
instrument equipped with flame ionization detector (FID) and a Restek Stabilwax fused-silica 
capillary column (length 60 m x 0.25 mm ID) was employed. Helium was used as the carrier gas with 
a flow rate of 1 mL/min and the oven temperature program was as follows—5 minutes at 60°C then 
a gradient of 5°C/minute to 220°C. One μL of sample was manually injected at 280°C into the Gas 
Chromatography injector in the splitless mode. Relative percentages for quantification of the 
components were calculated by electronic integration of the GC-FID peak areas. Identification of the 
constituents was performed on MS library search (Wiley and Nist). Linear retention indices (LRIs) of 
each compound were calculated using a mixture of aliphatic hydrocarbons (C8-C30, Ultrasci) injected 
directly into GC injector. 
2.7. Cytotoxicity Assays 
Human gingival fibroblasts were obtained as described from by Radicioni G. et al [26]. Cells 
were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum 
(FCS) and were not used beyond the fifth step. The cytotoxicity of serial dilutions of the mixture of 
C. aurantium var. amara EO (from 0.50% v/v to 0.03% v/v) and V. vinifera cv Italia Hy (from 50% v/v 
to 3.25% v/v) for 24 and 48 hours was evaluated. Untreated culture cells were used as control. 
Tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS] (Promega, Madison, WI, USA) was used, which was 
diluted in basic medium. Then, 1 × 104 cells were suspended in 200 mL of basic medium to be coated 
in 96-well cell culture plates and grown at confluence for 24 hours. Cell vitality was evaluated after 
the addition of the aforementioned serial dilutions at 37°C for 24 and 48 hours. The MTS analysis was 
performed according to the manufacturer's protocols. Each experiment was done in triplicate. 
2.8. Statistical Analysis 
All data obtained in triplicate from each experiment were expressed as means ± standard 
deviation (SD). The response of S. cerevisiae and C. albicans to C. aurantium var amara EO concentration 
was fitted by means of mathematical models, using the Sigma Plot 10 (Systat Software Inc., Chicago, 
IL, USA) software. The best fitting model was chosen between linear and exponential decay function. 
The two respective equations are: 
y = y0 + ax      (1) 
y = a × exp(−bx)  (2), 
where: y0, intercept; a, slope (Eq. (1)), initial level (Eq. (2)); b, rate constant. 
All the results obtained from the broth microdilution susceptibility testing were presented as 
relative values, assuming the average of S. cerevisiae and C. albicans as positive control (Ctrl+) = 100%. 
The data were treated with the GraphPad V 4.0 software. A two-way ANOVA for the factors clinical 
isolates (2 levels) and EO-Hy combined treatments (13 levels including Ctrl+) was run on these data. 
The CoStat 6.3 package (CoHort Software, Berkeley, CA, USA) was used for the ANOVA. 
All the results, obtained by cytotoxicity study, were expressed as mean percentage of vitality 
and data treated with GraphPad V 4.0 software. The treated group means were compared by analysis 
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of variance (ANOVA) followed by a multiple comparison of means using the Dunnett’s test. Values 
with p < 0.05 were considered significant. 
3. Results 
3.1. Antimicrobial Activities of EOs 
Table 1 shows the MIC values of the 38 Candida species isolated from IBS patients against the 
EOs of C. lemon, C. lemon var. femminello, C. reticulata, C. aurantium var. amara, C. zeylanicum and M. 
didyma tested at the 0.50% v/v to 0.06% v/v concentrations.  
Table 1. MIC values of selected clinical Candida spp. isolates against the essential oils in study. 
Designation Isolates 
MIC (% v/v) 
CL1 CL-f2 CR3 CA-a4 CZ5 MD6 
3.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
3.2 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.3 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.4 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.5 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.6 C. albicans >0.50 >0.50 >0.50 0.06 ≤0.06 0.25 
3.7 Pikia kudriavzeii >0.50 >0.50 >0.50 0.25 ≤0.06 0.25 
3.8 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.9 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.11 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.12 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.14 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.15 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
3.16 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.17 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.18 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25 
3.19 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.50 
5.2 C. parapsilosis >0.50 >0.50 >0.50 0.50 ≤0.06 0.12 
5.3 C. zeylanoides >0.50 >0.50 >0.50 0.50 ≤0.06 0.12 
5.4 C. parapsilosis >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
5.5 C. parapsilosis >0.50 >0.50 >0.50 >0.5 ≤0.06 0.25 
5.6 C. parapsilosis >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
8.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
9.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
10.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50 
10.2 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50 
10.3 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
10.4 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
10.5 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
10.6 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
10.7 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
10.8 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
11.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
11.2 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
14.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25 
18.2 C. glabrata >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50 
18.5 C. glabrata >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50 
18.6 C. glabrata >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50 
MIC values were found to be equal to the MFC values for all the isolates tested. 1C. limon. 2C. limon 
var. femminello. 3C. reticulata. 4C. aurantium var. amara. 5C. zeylanicum. 6M. dydima. 
The MIC50 values were > 0.50% v/v for C. lemon, C. lemon var. femminello and C. reticulata, 0.50% 
v/v for C. aurantium var. amara, ≤ 0.06% v/v for C. zeylanicum and 0.25% v/v for M. didyma.  
Table 2 shows the MIC values of the 7 probiotic strains and the 12 Galactomyces species and S. 
cerevisiae isolates against the EOs of C. aurantium var. amara, C. zeylanicum and M. didyma (the only 
three EOs showing better activity) tested at the 4.0% v/v to 0.06% v/v concentrations. It was chosen 
to test lower EO concentrations for the isolates from pathogenic species (i.e. Candida species) and 
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higher EO concentrations for the isolates from beneficial species (i.e. probiotic or Galactomyces/S. 
cerevisiae species). This choice would ensure the activity toward the pathogenic species and non-
toxicity toward the beneficial species eventually present in the gut microbiota of IBS patients. The 
MIC50 values were > 4.0% v/v for C. aurantium var. amara, 0.50% v/v for M. didyma and ≤ 0.06% v/v 
for C. zeylanicum. 
Table 2. MIC values of commercial probiotic strains and clinical beneficial bacterial strains against 
the essential oils of M. dydima, C. aurantium var. amara, C. zeylanicum. 
Strain Probiotic commercial strains 
MIC (% v/v) 
CA-a 1 CZ 2 MD 3 
CBS5926 S. boulardii >4.00 ≤0.06 0.50 
LA3SACCO L. acidophilus >4.00 ≤0.06 2.00 
LA-14 L. acidophilus >4.00 ≤0.06 0.50 
ATCC14917 L. plantarum >4.00 ≤0.06 1.00 
DSMZ 20021 L. rhamnosus >4.00 ≤0.06 0.50 
R0215 L. casei >4.00 ≤0.06 1.00 
R0052 L. helveticus 0.12 ≤0.06 0.12 
Designation Beneficial clinical strains    
13.0 Galactomyces species 2.00 ≤0.06 0.25 
17.1 Galactomyces species >4.00 ≤0.06 2.00 
17.5 Galactomyces species 4.00 ≤0.06 0.50 
17.7 Galactomyces species >4.00 ≤0.06 0.50 
17.8 Galactomyces species >4.00 ≤0.06 0,50 
17.9 Galactomyces species >4.00 ≤0.06 0.50 
17.10 Galactomyces species 4.00 ≤0.06 0.50 
17.11 Galactomyces species 4.00 ≤0.06 1.00 
14.3 S. cerevisiae 1.00 ≤0.06 0.25 
14.5 S. cerevisiae 1.00 ≤0.06 0.25 
14.9 S. cerevisiae 1.00 ≤0.06 0.50 
14.11 S. cerevisiae 2.00 ≤0.06 0.25 
MIC values were found to be equal to the MFC values for all the isolates tested. 1 C. aurantium var. 
amara, 2 C. zeylanicum, 3 M. dydima. 
Based on these findings, the C. aurantium var. amara, C. zeylanicum and M. didyma EOs were 
tested against two co-cultured clinical isolates of C. albicans (clinical isolate 3.1) and S. cerevisiae 
(clinical isolate 14.3), which were representative of both pathogenic and beneficial isolates included 
in the study. Using 4% v/v to 0.015% v/v concentrations, it was found that MIC and MFC values were 
equal for all the three EOs. Expectedly, the C. zeylanicum EO was the most effective (MFCs for C. 
albicans and S. cerevisiae, 0.015% v/v and 0.06% v/v, respectively), compared to the M. didyma EO 
(MFCs for C. albicans and S. cerevisiae, 1% v/v) and the C. aurantium var. amara EO (MFCs for C. albicans 
and S. cerevisiae, 2% v/v). Therefore, the inhibitory capability of the C. aurantium var. amara EO was 
further investigated by counting the cfu/mL of both C. albicans and S. cerevisiae recovered after their 
incubation with sub-MIC concentrations (≤ 2% v/v) of the EO. Figure 1 shows that the 2% 
concentration of C. aurantium var. amara EO was able to completely suppress both organisms. 
Interestingly, S. cerevisiae exhibited an exponential trend of increased tolerance to the EO (R² = 0.71) 
that was statistically significant and different (p < 0.05) from the linear trend of C. albicans (R² = 0.65). 
As expected, neither M. dydima nor V. vinifera cv Italia Hys showed antimicrobial activities 
against all the 59 microbial strains above mentioned. 
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Figure 1. cfu/ml of Saccharomyces cerevisiae (filled symbol) and Candida albicans (empty symbol) in 
response to Citrus aurantium var. amara essential oil (EO) concentration. Solid line, exponential decay 
function (Eq. (2)) describing S. cerevisiae abatement at increasing EO concentration. Dashed line, linear 
function (Eq. (1)) describing C. albicans abatement at increasing EO concentration. (+) and *, significant 
at p ≤ 0.10 and p ≤ 0.05, respectively. 
3.2. Immunomodulatory and Antioxidant Activities of the V. vinifera cv Italia Hy 
The immunomodulatory activities of both V. vinifera cv Italia and M. didyma Hys were studied, 
using human PBMCs. Data showed that PBMCs treated with M. didyma Hy died whereas those 
treated with V. vinifera cv Italia Hy did not lose viability. Therefore, the effects of the V. vinifera cv 
Italia Hy and, in parallel, LPS alone or in combination with the Hy has been investigated, on the levels 
of IL-10 and TNF- produced by PBMCs.  
Table 3 summarizes both the mean and standard deviation values of IL-10 and TNF- under the 
tested conditions, while figure 2 shows the relationship of the two cytokines in each condition.  
Table 3. IL-10 and TNF-values of both peripheral blood mononuclear cells (PBMCs) and PBMCs 
stimulated with lipopolysaccharide (LPS) when treated with the Hy of V. vinifera alone or in 
combination with the EO of C. aurantium var. amara. 
Simple 
VV-Hy1 CA-EO2 Mean (± St. Dev.)3 
(%v/v) (%v/v) IL-10 TNF- 
PBMCs - - 2.60 (± 0.07) 47.98 (± 2.80) 
 50.00 - 16.40 (± 0.80) 199.50 (± 12.30) 
 25.00 - 53.80 (± 10.20) 375.80 (± 7.20) 
 12.50 - 14.51 (± 0.60) 1126.80 (± 14.80) 
 6.25 - 3.28 (± 0.30) 620.60 (± 33.20) 
PBMCs + LPS - - 518.00 (± 3.00) 2002.90 (±14.40) 
 50.00 - 5.93 (± 0.30) 238.70 (± 7.50) 
 25.00 - 90.90 (± 3.60) 1846.30 (± 20.30) 
 12.50 - 83.70 (± 4.20) 2221.50 (± 2.60) 
 6.25 - 46.30 (± 0.90) 2148.20 (± 195.6) 
 50.00 0.5 0.64 (± 0.14) 0.64 (± 0.14) 
 25.00 0.25 119.00 (± 0.46) 977.91 (± 16.60) 
 12.50 0.12 269.53 (± 4.07) 1901.90 (± 0.00) 
 6.25 0.06 403.23 (± 37.65) 2143.01 (± 25.09) 
1 hydrolate of V. vinifera cv Italia, 2Essential oil of C. aurantium var. amara, 3values are expressed as pg/mL. 
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Figure 2. Variation of the amount of cytokines IL-10 and TNF- in the medium culture of PBMCs 
treated with scalar dilutions of the V. vinifera cv Italia Hy alone or in combination with EO and/or 
LPS. The circle-shaped indicators refer to the samples treated with the Hy only; the squares are 
referred to the samples treated with the Hy plus LPS, while the triangles show the samples treated 
with Hy plus the EO of C. aurantium var. amara plus LPS. The white rhombus is the untreated control 
and the black rhombus is the control treated with LPS. Letters a, b, c and d indicate samples treated 
with scalar dilution of the Hy (50% v/v, 25% v/v, 12.50% v/v and 0.06% v/v respectively). Letters e, f, 
g and h are referred to samples treated with scalar dilution of the Hy (50% v/v, 25% v/v, 12.50% v/v 
and 0.06% v/v respectively) and LPS (1gr/mL). Letters i, l, m and n are referred to PBMCs treated 
with a 1:100 v/v mixture of the Hy, (50% v/v, 25% v/v, 12.50% v/v and 0.06% v/v respectively) and the 
EO (0.50% v/v, 0.25% v/v, 0.12% v/v and 0.06% v/v respectively) plus LPS. 
As shown in table 3, the levels of IL-10 and TNF- in untreated PBMCs were 2.6 ± 0.07 pg/mL 
and 47.98 ± 2.8 pg/mL, respectively, whereas those in PBMCs treated with LPS were 518 pg/mL ± 3.0 
pg/mL and 2002.9 pg/mL ±14.4 pg/mL. The IL-10 and TNF- values of PBMCs treated with 50% of 
the V. vinifera cv Italia Hy and those of PBMCs treated with both 50% of the V. vinifera cv Italia Hy 
and LPS had values close to those of the untreated PBMCs (Figure 2, letters a and e in CTR circle). 
The values of PBMCs treated with concentrations other than 50% of V. vinifera cv Italia Hy alone 
varied based on the Hy concentration tested. In particular, only TNF- values were higher than those 
of PBMCs, while both IL-10 and TNF- values were lower than those of PBMCs stimulated with LPS 
alone (Figure 2, letters b, c, d in Hy circle). PBMCs treated with concentrations other than 50% of V. 
vinifera cv Italia Hy in combination with LPS had a strong reduction of IL-10 values, compared to 
PBMCs stimulated with LPS only. 
The DPPH assay was used to study the anti-oxidant activity of the V. vinifera cv Italia Hy. Data 
show that the Hy exhibited low activity because of an IC50 of 4 ×10-3 ± 0.001 g/L of organic 
component, which corresponds to the one present in a 95.6 ± 2.1% v/v of Hy solution (i.e. to the one 
of the almost pure Hy).  
3.3. Effectiveness of the C. aurantium var. Amara EO and V. vinifera cv Italia Hy Combination 
Figure 3 shows the results of checkerboard BMD testing of C. aurantium var. amara EO (from 
0.50% v/v to 0.06% v/v) and V. vinifera cv Italia Hy (from 25% v/v to 6.25% v/v) against C. albicans 
(clinical isolate 3.1) and S. cerevisiae (clinical isolate 14.3). As showed by ANOVA test, concentrations 
equal to or lower than 0.12% v/v for EO, regardless of Hy concentration, did not produce any 
statistically significant inhibition for the two isolates, whereas for concentrations of the EO higher 
than 0.12% v/v the isolate of S. cerevisiae shows a statistically significant growth inhibition.  
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Figure 3. Relative growth of the clinical isolates of C. albicans (3.1) and S. cerevisiae (14.3) when 
cultured in presence of scalar dilutions of both the EO of C. aurantium var amara and the Hy of V. 
vinifera cv Italia. The values are relative to the positive control (CTR+) and are expressed in percentage. 
The average of the two isolates’ positive controls is set at 100%.  
Then, 1:100 v/v mixtures of EO (0.50% v/v to 0.06% v/v) and Hy (50% v/v to 6.25%) were 
evaluated for morphological microscopy examination and five of seven Candida species (exceptions 
were one C. glabrata and one C. tropicalis [0.4 R]) isolates displayed a concentration-dependent 
reduced capability of forming hyphal filaments (Table 4). As expected, any morphological alterations 
for the S. cerevisiae isolate tested were observed. Additionally, none of the EO/Hy mixture 
concentrations was able to affect the nine probiotic isolates as well the A. muciniphila and F. prausnitzii 
isolates (potentially usable as probiotics). 
It was assessed whether the EO/Hy mixture concentrations had immunomodulatory activities 
on human PBMCs when used in combination with LPS.  
As shown in Figure 2, a linear decrease of IL-10 and TNF- values were observed in PBMCs 
treated with both LPS and different concentrations of the EO/Hy mixture. In particular, at the lowest 
concentration tested (6.25% v/v Hy and 0.625% v/v EO) the values of cytokines are similar to those 
expressed by the PBMC stimulated with LPS only. Whereas, by increasing the tested concentrations 
of the EO/Hy mixture, the IL-10 and TNF- values decrease linearly (Figure 2, letters l, m and n in 
Mix + LPS circle) until they become similar to those of the PBMCs (Figure 2, letter i in CTR circle).  
Table 4. Effectiveness of a mixture of C. aurantium var. amara EO and V. vinifera cv italia Hy on the 
morphology of clinical fungal species. 
Designation 
Fungal 
species 
C. aurantium va. amara (% v/v) EO + V. vinifera Hy  
  0.50 + 50 0.25 + 25 0.12 + 12.5 0.06 + 6.25 0.03 + 3.17 CTR 
0.3R 1 C. tropicalis Y H H H H H++ 
0.4R 1 C. tropicalis  
H++ (no 
adhesion) 
H++ (no 
adhesion) 
H++ (no 
adhesion) 
H++ (no 
adhesion) 
H++ (no 
adhesion) 
H++ 
3.1 C. albicans Y H H+ H+ H+ + 
10.1 C. albicans Y H H+ H+ H++ H++ 
3.15 C. albicans Y Y Y Y H+ H++ 
8.5 C. glabrata Y Y Y Y Y Y 
3.7 C. krusei Y Y Y Y Y Y 
5.1 
C. 
parapsilosis 
Y Y Y Y Y Y 
1 fluconazole resistant strain, Y =Presence of a lot of yeast; H = Presence of rare hyphae; H+ = few 
hyphae and pseudo-hyphae, H++ = a lot of hyphae and pseudo-hyphae. 
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Furthermore, it was investigated whether the EO/Hy mixture concentrations had cytotoxic 
activities on human gingival fibroblasts. As shown in Figure 4, none of the concentrations tested was 
capable of producing statistically significant effects on the fibroblasts after 24 h and 48 h of incubation. 
 
Figure 4. Cytotoxicity tests. Cytotoxicity assays performed with a Cell Titer Blue viability assay on 
human gingival fibroblasts at 24 (A) and 48 hrs (B) upon cell synchronization (24hrs). Cells were 
treated with scalar dilution of a 1:100 v/v mixtures of Citrus aurantium var. amara EO (0.50% v/v to 
0.06% v/v) and Vitis vinifera cv Italia Hy (50% v/v to 6.25%). 
Finally, GC-MS analyses performed on both the EO and the organic fraction from Hy showed 
that the major component of EO was the limonene (93.93%) and the major components of the Hy 
were limonene (17.68%), cis-geraniol (25.40%) and -linalool (38.81%) (Table 5). 
Table 5. Chemical composition (%) of C. aurantium var. amara EO and V. vinifera Hy. 
Name 1 LRI 2 LRIlit 3  %CA-EO 4 %VV-Hy 5 
α -pinene 1038 1040 0.57 0.39 
β -pinene 1134 1130 0.73 - 
sabinene 1152 1156 0.36 - 
β -myrcene 1171 1167 2.37 - 
limonene 1232 1235 93.93 17.68 
γ-terpinene 1270 1263 0.26 - 
o-cymene 1295 1287 0.15 - 
cis-linaloloxide 1433 1420 - 0.85 
decanal 1520 1515 0.22 - 
β -linalol 1553 1547 0.21 38.81 
linalyl acetate 1572 1575 0.77 - 
α -terpineol 1705 1700 0.22 7.55 
borneol 1724 1717 - 0.69 
cis-geraniol 1831 1823 - 25.40 
humulene-1,2-epoxide 2018 NA* - 2.55 
d-nerolidol 2030 2023 0.21 - 
thymol 2198 2189 - 1.75 
carvacrol 2231 2225 - 4.33 
SUM   100.00 100.00 
1 Elution order on polar column; 2 Linear Retention indices measured on polar column; 3 Linear 
Retention indices from literature; 4 Essential oil of C. aurantium var. amara, 5 hydrolate of V. vinifera cv 
Italia, * Normal Alkane RI. The %VV-Hy are referred to the fraction of organic components extracted 
from 50mL of Hy.  
4. Discussion 
Few studies have been done on the effectiveness of essential oils in treating patients with IBS 
and most of them have been made in the last 10 years. In addition to the now known properties of 
the essential oil of Mentha × piperita that make it an interesting treatment not only for IBD but also for 
IBS [22], other essential oils, especially those obtained from aromatic plants with known carminative 
activity, have been recently studied in the treatment of IBS. Mahboubi M. [18] reviewed the action of 
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Zataria multiflora EOs in the treatment of gastrointestinal problems, especially in IBS. As reported, 60 
drops oral daily dose of Z. multiflora essential oil (2%) can relieve the symptoms of IBS without any 
adverse effects. Portincasa P. et al [20] and Di Ciaula A. et al [16] investigated the activity of the EOs 
of F. vulgaris in association with Curcuma longa extract in IBS patients. The two studies concluded that 
the administration of these natural compounds significantly improved symptoms and quality of life 
in IBS patients within 2 months from the treatment. Mosaffa-Jahromi M. et al [19] have demonstrated 
that a treatment of 4 weeks with encapsulated P.anisum EO (200 mg for 3 times a day) is able to 
improve IBS symptoms better than placebo or M. piperita capsules (Colpermin®) (p < 0.0001). Finally, 
Agah S. et al [27] studied the effect of 20 drops of Cuminum cyminum EO on 57 patients with IBS 
selected according to the ROME II diagnostic criteria. Data showed that IBS symptoms had a 
statistically significant reduction during and after treatment. 
According to the most recent literature, at the base of the IBS there is an alteration of the intestinal 
microbiota in favor of microbial strains generally present in lower percentages (especially fungal 
strains). For this reason, we chose to investigate the antimicrobial action of some EOs and Hys on 
both fungal and probiotic strains. All the natural products studied were obtained from plants 
potentially cultivable in the Mediterranean area with the exception of C. zeylanicum, which was taken 
as a reference given its known high antimicrobial activity [28]. Furthermore, considering that the IBS 
symptoms are deeply conditioned by an altered brain-gut-microbiome axis, some of the EOs in study 
have been chosen to potentially act not only on microbial strains but also on the central nervous 
system (CNS). Therefore, 4 out of the 6 EOs studied belong to the Citrus genus which, besides being 
a genus widely present in Italy, is mainly used in aromatherapy in the treatment of nervous disorders 
and anxiety. Particularly, the C. aurantium var. amara EO is used as a natural mild sedative, hypnotic 
and anticonvulsant agent. It is used in treating insomnia, sleep disorders, anxiety, epilepsy and 
seizures. It has been also reported for its anti-spasmodic effects and, thanks to the presence of 
limonene, for its gastro-protective and ulcer healing actions by increasing the gastric production of 
mucus, which is useful as a secondary intervention in the treatment of chronic inflammatory diseases. 
Similarly, C. limon and C. reticulata EOs are used in phytotherapy to relieve symptoms of anxiety [29]. 
Instead, the M. didyma is an aromatic plant included in the BELFRIT (Belgium, France and Italy) list, 
native of Northern Europe but cultivable in Italy; its EO has two phenols as major components 
(thymol and carvacrol) and therefore shows a marked antimicrobial activity [24]. 
The study of MICs (and MCCs), against clinical isolates of Candida spp., indicates that no EOs 
belonging to the Citrus genus have an action comparable to that of M. didyma (MIC50 = 0.25% v/v) 
and C. zeylanicum (MIC50 ≤ 0.06 % v/v) EOs. All the EOs obtained from Citrus have a MIC50 > 0.5 % 
v/v with the exception of the EO of C. aurantium var. amara that showed a MIC50 = 0.50% v/v, slightly 
different from that of M. didyma. Based on this result, the action of the 3 EOs with major antifungal 
activity has been tested towards both probiotic strains and beneficial clinical isolates belonging to the 
intestinal microbiota (Table 2). The data indicate that both the above are generally more resistant to 
the action of EOs than the pathogenic fungal isolates. In particular, the EO of C. aurantium var. amara 
has a MIC50 value (MIC50 ≥ 4% v/v) at least 3 dilutions higher against the beneficial clinical isolates 
than against the clinical isolates of Candida species (MIC50 = 0.50% v/v). 
These data are in agreement with those available in the literature highlighting that the probiotic 
strains have higher MIC values than the pathogenic strains [3,30,31] and that thanks to the different 
MIC values between probiotic and pathogenic strains it is possible to administer probiotics and EOs 
together to cure pathogenic infections in human gut [32]. 
To evaluate the effectiveness of the three best EOs on the rebalance of beneficial and pathological 
clinical strains, we performed the BMD susceptibility tests using the EOs of C. aurantium var. amara, 
M. dydima and C. zeylanicum against two co-cultured randomly selected fungal clinical isolates (C. 
albicans clinical isolate 3.1 and S. cerevisiae clinical isolate 14.3). 
The choice to co-culture one clinical isolate of C. albicans with one of S. cerevisiae is motivated by 
the evidence that in IBS patients a greater colonization of fungal strains belonging to the genus 
Candida, at the expense of the ones of S. cerevisiae, has been demonstrated [4,5,33]. If on the one hand 
it is known that S. cerevisiae is a yeast generally well represented in the intestinal microbiota of healthy 
Nutrients 2020, 12, 1329 13 of 16 
 
subjects that, besides having a known anti-inflammatory action, is able to compete for the territory 
with Candida spp., on the other we know that IBS patients are characterized by a higher abundance 
of C. albicans (61.8%) compared to healthy subjects (48.75%) [33]. Moreover, IBS C. albicans isolates 
were different from those of healthy subjects not only genotypically but also phenotypically as these 
clinical isolates of C. albicans were able to grow at high temperatures and low pH compared to those 
isolated from healthy subjects [33]. These data suggest that IBS could be characterized by the presence 
of potentially virulent C. albicans strains and motivate our choice. 
Our data show that, when co-cultured, the two fungi have the same MFC but, by analyzing the 
fungal growth in the presence of sub-MIC of C. aurantium var. amara EO, it is possible to identify a 
different modulating action of this EO towards the two clinical strains. In particular, for 
concentrations equal to or lower than 2% v/v of C. aurantium var. amara EO, the strain of C. albicans is 
significantly more inhibited than that of S. cerevisiae (Figure 1). Therefore, this activity could be useful 
in an attempt to rebalance the relative abundance of each clinical species in IBS patients. 
The variation of the intestinal microbiota also involves the variation of the intestinal 
inflammatory microenvironment. Indeed, it is known that the decrease in S. cerevisiae and the increase 
in Candida species is generally related to an increase in the pro-inflammatory pattern in IBS patients 
[5]. As described in Results, an interesting immunomodulatory and anti-oxidant property of the V. 
vinifera cv Italia Hy was identified; on the contrary, the Hy of M. dydima was excluded because toxic 
for human PBMCs culture. 
The V. vinifera is a plant genus recognized by both traditional and consolidated use for the 
treatment of microcirculation problems thanks to its important anti-oxidant, anti-inflammatory, 
spasmolytic and immunomodulated actions. The first sources on the use of V. vinifera as medicament 
are the Egyptian papyri, the Sumerian tablets, the writings of Hippocrates of Cos, Celsus, Galen and 
Paracelsus. Currently, natural products obtained from V. vinifera are found on the market in the form 
of dry extracts or soft aqueous extracts [34–36] but it is hard to find the hydrolate of V. vinifera because 
it is an unusual natural product obtained from the distillation of a non-aromatic plant. This means 
that our data are innovative showing that it is obtained from a still unexplored natural product that, 
thanks to its immunomodulatory and anti-oxidant activity, could be exploited in the chronic low-
grade inflammation that establishes in patients with IBS [37]. 
Tests developed to identify the best combination of C. aurantium var. amara EO and V. vinifera cv 
Italia Hy have shown that a serial dilution of a mixture made with a 1:100 ratio of the two natural 
products (starting from a concentration of 0.50% v/v of C. aurantium var. amara EO and 50% v/v of V. 
vinifera cv Italia Hy) caused an interesting inhibition of the ability of C. albicans species to form hyphae 
(Table 4). As reported in a recent review, the morphological plasticity of Candida albicans cells makes 
this fungus able to adapt to the different niches present in the gut of the host organisms. Generally, 
the production of C. albicans hyphae and pseudo-hyphae is typical of cellular models of virulence 
specialized in the commensalism [38]. The above are in agreement with what has been observed on 
C. albicans clinical isolates of IBS patients [33] where the gut microbiota is characterized by a greater 
abundance of C. albicans cells, more virulent than in healthy subjects. In this context, the use of one of 
the effective serial dilutions based on C. aurantium var. amara EO and V. vinifera cv Italia Hy, able to 
inhibit the production of hyphae and pseudo-hyphae of C. albicans strains, could prove to be 
successful in IBS treatment; especially considering that the same serial dilution of the two natural 
compounds also has the ability to linearly inhibit in a concentration-dependent manner the 
production of the IL-10 and TNF-cytokines from PBMCs grown in presence of the pro-
inflammatory stimulus (LPS) (Figure 2). Rather than the use of intestinal cells such as CaCo2, the ex 
vivo experiments carried out on PBMC were performed in order to evaluate the action of natural 
compounds in modulating the human systemic immunological response. This latter activity would 
enhance the effectiveness of the mixture inducing the reduction of the pro-inflammatory framework 
generally present in patients and able to favoring the growth of Candida species and promoting the 
establishment of the appropriate microenvironment for the development of beneficial probiotic 
strains including A. muciniphila and F. prausnitzii recently proposed as markers of the syndrome [39]. 
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Finally, the mixture identified in this study appears to be suitable for an oral use in patients with 
IBS because, in addition to showing no in vitro cytotoxic activity (Figure 4), it appeared to be 
composed mainly of the monoterpene limonene because all the other chemical constituents were 
present in traces (Table 5). In a study, the limonene has been designated as a compound with low 
oral toxicity based on its lethal dose (LD50) and repeated-dose toxicity studies. Therefore, except for 
topical applications, for which attention must be paid to avoid its irritating potential, the use of 
limonene is widely granted in the pharmaceutical, cosmetic and food industries for its many 
properties [40]. 
5. Conclusions 
In conclusion, even though further in vivo studies to evaluate the effectiveness as well as the 
possible presence of adverse and/or toxic effects are necessary, our study concludes that a mixture 
based on C. aurantium var. amara EO and V. vinifera cv Italia Hy (ratio 1:100) can be useful in the 
treatment of IBS. The use of this mixture in an integrated treatment with conventional treatments 
could favor the growth of both probiotic and beneficial gut strains, disfavoring pathogenic fungal 
strains and rebalancing the intestinal inflammatory microenvironment through the reduction of the 
expression of IL-10 and TNF-cytokines and, in parallel, of the pro-inflammatory 
microenvironment. 
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